MRSN: Mersana Therapeutics, Inc.
About
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Current Value
$2.251 Year Return
Current Value
$2.251 Year Return
Key Details
Market Cap
$274.24M
P/E Ratio
-3.62
1Y Stock Return
40.51%
1Y Revenue Growth
-14.70%
Dividend Yield
0.00%
Price to Book
260.0
Strategies that include MRSN
Stock's related to MRSN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACEL | 40.40% | $940.36M | +12.85% | 0.00% |
| CRNX | 39.68% | $5.12B | +84.27% | 0.00% |
| VRDN | 39.67% | $1.60B | +28.92% | 0.00% |
| IBEX | 38.93% | $333.12M | +12.01% | 0.00% |
| NTRA | 38.65% | $21.40B | +200.46% | 0.00% |
| ALEC | 38.61% | $377.04M | -19.46% | 0.00% |
| ALTG | 38.23% | $236.78M | -29.08% | 3.22% |
| RPTX | 38.05% | $122.43M | -39.50% | 0.00% |
| PGEN | 37.95% | $228.91M | -28.00% | 0.00% |
| RCEL | 36.92% | $321.96M | +27.43% | 0.00% |
| ALLO | 36.90% | $444.50M | -24.82% | 0.00% |
| PRTA | 35.82% | $756.01M | -56.52% | 0.00% |
| MCFT | 35.55% | $344.65M | -0.29% | 0.00% |
| MTRX | 35.30% | $358.21M | +30.13% | 0.00% |
| FATE | 35.12% | $248.29M | -11.02% | 0.00% |
| SEER | 35.09% | $134.44M | +40.74% | 0.00% |
| KOD | 34.99% | $296.80M | +150.67% | 0.00% |
| MGTX | 34.87% | $467.36M | +9.12% | 0.00% |
| SAGE | 34.67% | $300.36M | -74.61% | 0.00% |
| RGNX | 34.37% | $473.65M | -51.96% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CLX | <0.01% | $20.81B | +20.66% | 2.88% |
| KLG | 0.01% | $1.48B | +45.15% | 3.71% |
| ED | -0.03% | $33.59B | +7.16% | 3.43% |
| PGR | 0.05% | $149.10B | +57.29% | 0.45% |
| PTMN | 0.09% | - | - | 16.06% |
| HPK | -0.09% | $1.86B | -9.44% | 0.81% |
| IMXI | 0.11% | $651.21M | -1.55% | 0.00% |
| CNSL | 0.12% | $548.51M | +9.98% | 0.00% |
| XOM | 0.14% | $521.39B | +13.56% | 3.22% |
| WHLM | 0.16% | $17.64M | -29.34% | 0.00% |
| EIG | -0.18% | $1.30B | +38.83% | 2.25% |
| SIGA | 0.20% | $446.99M | +29.99% | 0.00% |
| DAO | 0.22% | $159.28M | +25.62% | 0.00% |
| FHI | -0.24% | $3.38B | +35.20% | 2.93% |
| RELX | 0.24% | $84.12B | +19.85% | 1.71% |
| WM | -0.24% | $87.92B | +27.58% | 1.34% |
| SNY | 0.24% | $120.34B | +3.11% | 4.25% |
| SMC | -0.25% | $383.35M | +97.26% | 0.00% |
| LRN | -0.27% | $4.43B | +74.97% | 0.00% |
| DKL | 0.27% | $2.03B | -18.84% | 10.94% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MNOV | -20.13% | $93.19M | +2.15% | 0.00% |
| CME | -16.90% | $82.76B | +9.21% | 1.98% |
| ORLY | -14.88% | $69.31B | +22.06% | 0.00% |
| MNR | -12.41% | $1.66B | -10.71% | 15.90% |
| AGS | -11.88% | $479.25M | +57.18% | 0.00% |
| OCX | -11.82% | $42.93M | -36.09% | 0.00% |
| PEP | -11.72% | $215.02B | -6.60% | 3.35% |
| ES | -11.19% | $22.60B | +4.85% | 4.58% |
| XEL | -10.48% | $41.42B | +15.91% | 3.12% |
| KO | -9.95% | $269.63B | +7.86% | 3.07% |
| CBOE | -9.85% | $21.46B | +15.84% | 1.11% |
| MCK | -9.68% | $78.15B | +35.51% | 0.42% |
| GIS | -9.43% | $34.85B | -2.91% | 3.78% |
| SOC | -9.42% | $1.93B | +74.70% | 0.00% |
| PG | -8.78% | $402.15B | +14.14% | 2.33% |
| AFL | -8.74% | $61.74B | +35.69% | 1.35% |
| MO | -8.70% | $94.67B | +37.05% | 7.07% |
| LTM | -8.12% | $8.51B | -100.00% | <0.01% |
| STG | -8.05% | $35.67M | +7.92% | 0.00% |
| USM | -7.97% | $5.35B | +41.82% | 0.00% |
ETF's related to MRSN
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -32.74% | $388.04M | 1.43% |
| VIXY | -25.09% | $195.31M | 0.85% |
| TAIL | -14.69% | $67.98M | 0.59% |
| XBIL | -11.59% | $637.70M | 0.15% |
| KMLM | -7.41% | $353.87M | 0.9% |
| KRBN | -7.30% | $242.47M | 0.85% |
| UUP | -7.27% | $309.25M | 0.77% |
| HDRO | -7.13% | $164.26M | 0.3% |
| TBIL | -6.56% | $4.38B | 0.15% |
| SGOV | -6.52% | $27.53B | 0.09% |
| EQLS | -5.60% | $76.08M | 1% |
| USDU | -5.24% | $201.97M | 0.5% |
| WEAT | -4.89% | $120.27M | 0.28% |
| CSHI | -4.86% | $482.85M | 0.38% |
| CTA | -4.75% | $350.27M | 0.78% |
| MINT | -4.58% | $11.62B | 0.35% |
| CANE | -4.09% | $17.72M | 0.29% |
| IYK | -2.72% | $1.30B | 0.4% |
| FLRN | -1.98% | $2.33B | 0.15% |
| AGZD | -1.94% | $142.76M | 0.23% |
News
Yahoo
Mersana Therapeutics Inc (MRSN) reports significant financial improvements and promising clinical trial progress, positioning the company for future growth.
Yahoo
Q3 2024 Mersana Therapeutics Inc Earnings Call
SeekingAlpha
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ETCompany ParticipantsJason Fredette - SVP, IRMartin...
Yahoo
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 50% and 32.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
SeekingAlpha
The following slide deck was published by Mersana Therapeutics, Inc.
Yahoo
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business updat
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.